High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration

Autor: Svetlana Kudryavtseva, E. Maryukhnich, Alexey A. Komissarov, Ivan Molodtsov, O. Ivanova, Elena Vasilieva, Alexey Mazus, Evgeniy Nikonov
Jazyk: angličtina
Rok vydání: 2021
Předmět:
RNA viruses
Viral Diseases
Coronaviruses
Physiology
Respiratory System
Artificial Gene Amplification and Extension
030204 cardiovascular system & hematology
Polymerase Chain Reaction
Severity of Illness Index
Russia
Geographical Locations
0302 clinical medicine
Medical Conditions
Nasopharynx
Epidemiology
Public and Occupational Health
030212 general & internal medicine
Pathology and laboratory medicine
Virus Testing
Multidisciplinary
Medical microbiology
Viral Load
Vaccination and Immunization
Body Fluids
Europe
Infectious Diseases
Blood
Viruses
Medicine
RNA
Viral
SARS CoV 2
Pathogens
Anatomy
Viral load
medicine.drug
Research Article
Hydroxychloroquine
medicine.medical_specialty
Asia
SARS coronavirus
Science
Immunology
Research and Analysis Methods
Microbiology
Virus
03 medical and health sciences
Pharmacotherapy
Antiviral Therapy
Diagnostic Medicine
Internal medicine
Severity of illness
medicine
Humans
Viral shedding
Risk factor
Molecular Biology Techniques
Molecular Biology
Medicine and health sciences
Biology and life sciences
business.industry
SARS-CoV-2
Organisms
Viral pathogens
COVID-19
Covid 19
Microbial pathogens
COVID-19 Drug Treatment
People and Places
Pharynx
Preventive Medicine
business
Digestive System
Zdroj: PLoS ONE
PLoS ONE, Vol 16, Iss 1, p e0246396 (2021)
ISSN: 1932-6203
Popis: Because of the constantly growing numbers of COVID-19 infections and deaths, attempts were undertaken to find drugs with anti-SARS-CoV-2 activity among ones already approved for other pathologies. In the framework of such attempts, in a number of in vitro, as well as in vivo, models it was shown that hydroxychloroquine (HCQ) has an effect against SARS-CoV-2. While there were not enough clinical data to support the use of HCQ, several countries including Russia have included HCQ in treatment protocols for infected patients and for prophylaxis. In the current non-randomized, observational study we evaluated the SARS-CoV-2 RNA in nasopharynx swabs from infected patients 7–10 days post symptoms with clinically mild disease and compared the viral RNA load dynamics between patients receiving HCQ (200 mg twice per day according to the Ministry of Health of Russian Federation treatment instructions, n = 33) and a control group without antiviral pharmacological therapy (n = 12). We found a statistically significant relationship between maximal RNA quantity and deterioration of patients’ medical conditions, and as well we confirmed arterial hypertension to be a risk factor for people with COVID-19. However, we showed that at the dose used in the study HCQ therapy neither shortened the viral shedding period nor reduced the virus RNA load.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje